1 enrolling by invitation. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Enrolling by invitation 1 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Heart Valve Diseases: new trials by email Literature Review of Heart Valve Diseases trials Research Report on Heart Valve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM Aficamten (5 - 20 mg) - Symptomatic Hypertrophic Cardiomyopathy (HCM) | Phase 2 / Phase 3 | Enrolling by invitation | Cytokinetics | 900 | 2021-05-06 | 2026-10-13 |
Cardiomyopathy, Hypertrophic (1)
Aortic Stenosis, Subvalvular (1) · Aortic Valve Disease (1) · Aortic Valve Stenosis (1) · Cardiomyopathies (1) · Cardiovascular Diseases (1) · Heart Diseases (1)
Cytokinetics (1)
Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Iceland (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1)
PMID 39477631, PMID 40285763, PMID 40540987, PMID 42641848
2023 (1)